keyword
MENU ▼
Read by QxMD icon Read
search

HBV and renal transplantation

keyword
https://www.readbyqxmd.com/read/30213015/utilization-of-extracorporeal-membrane-oxygenation-for-a-severe-cardiocirculatory-dysfunction-recipient-in-liver-transplantation-a-case-report
#1
Xiaodong Sun, Wei Qiu, Yuguo Chen, Guoyue Lv, Zhongqi Fan
RATIONALE: Severe cardiac dysfunction or severe pulmonary hypertension is a contraindication of liver transplantation (LT). Extracorporeal membrane oxygenation (ECMO) is an advanced therapy for severe lung and/or cardiocirculatory dysfunction or failure. The application of ECMO to patients during the LT perioperative period may help recipients with severe cardiac disease to maintain the heart function and alleviate the reperfusion syndrome. PATIENT CONCERNS: A female liver recipient complained about weakness for 6 months...
September 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29716597/hepatitis-e-virus-infection-in-turkey-a-systematic-review
#2
REVIEW
Hakan Leblebicioglu, Resat Ozaras
Hepatitis E virus (HEV), a non-enveloped single stranded RNA virus causes sporadic cases of hepatitis or outbreaks. The disease is generally self-limited although it may cause fulminant hepatitis in pregnant women, elderly, those with underlying chronic hepatitis, immunosuppressed, and transplant recipients. It is transmitted through fecal-oral route and zoonotic transmission. Hepatitis is a main health care problem in Turkey; HBV and HCV prevalences are 4 and 1% respectively. Hepatitis D represents another considerable hepatitis etiology with a prevalence of 5-27%...
May 2, 2018: Annals of Clinical Microbiology and Antimicrobials
https://www.readbyqxmd.com/read/29696373/risk-factors-for-early-viral-infections-after-liver-transplantation
#3
Cornelius Johannes Busch, Benedikt Hermann Siegler, Heike Werle, Christoph Lichtenstern, Thomas Bruckner, Alexandra Heininger, Arianeb Mehrabi, Karl Heinz Weiss, Markus Alexander Weigand, Marcel Hochreiter
PURPOSE: Viral infections represent a serious threat for patients after liver transplantation (LT). The identification of risk factors during the early post-transplant period might help to improve prevention of viral infections after LT. METHODS: Between 2004 and 2010, 530 adult patients underwent LT at a large university hospital serving a metropolitan region in Europe. This retrospective single-centre study analysed putative risk factors for early viral infections with herpes simplex virus-1 (HSV-1), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), hepatitis A/B/C (HAV/HBV/HCV) and cytomegalovirus (CMV) in the first 3 months after LT...
June 2018: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/29603431/durability-of-the-hepatitis-b-vaccination-in-pediatric-renal-transplant-recipients
#4
Hilary Miller-Handley, Grant Paulsen, David K Hooper, Michael Lake, Danielle Lazear, Lara Danziger-Isakov
Since hepatitis B virus (HBV) vaccine implementation, HBV infection has significantly decreased. However, adult renal transplant recipients show a higher rate of seroreversion compared to the general population, leading to HBV infection risk. Data are limited in pediatric renal transplant recipients. Retrospective data were collected to determine the seroprotection and durability of HBV vaccination in pediatric renal transplant patients from 2004 to 2014. One hundred subjects were categorized based on pre- and post-transplant hepatitis B surface antibody (HBsAb)...
May 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29527269/outcomes-of-kidney-transplantation-in-patients-with-hepatitis-b-virus-infection-a-systematic-review-and-meta-analysis
#5
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn
AIM: To assess outcomes of kidney transplantation including patient and allograft outcomes in recipients with hepatitis B virus (HBV) infection, and the trends of patient's outcomes overtime. METHODS: A literature search was conducted using MEDLINE, EMBASE and Cochrane Database from inception through October 2017. Studies that reported odds ratios (OR) of mortality or renal allograft failure after kidney transplantation in patients with HBV [defined as hepatitis B surface antigen (HBsAg) positive] were included...
February 27, 2018: World Journal of Hepatology
https://www.readbyqxmd.com/read/29498197/hard-to-place-kidney-offers-donor-and-system-level-predictors-of-discard
#6
J Reinier F Narvaez, Jing Nie, Katia Noyes, Mary Leeman, Liise K Kayler
Understanding risk factors for deceased-donor kidney nontransplantation is important since discard rates remain high. We analyzed DonorNet® data of consecutive deceased-donor nonmandatory share primary kidney-only offers to adult candidates at our center and beyond between July 1, 2015 and March 31, 2016 for donor- and system-level risk factors of discard, defined as nontransplantation at our or subsequent transplant centers. Exclusions were hepatitis C virus/hepatitis B virus core antibody status, blood type AB, and donor <1 year based on low candidate waitlist size...
November 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29359868/personalized-subcutaneous-administration-of-hepatitis-b-surface-antibodies-without-nucleos-t-ide-analogs-for-patients-at-risk-of-renal-failure-after-liver-transplantation-a-prospective-single-center-cohort-study
#7
Rob Bielen, Geert Robaeys, Sigrid Schelfhout, Diethard Monbaliu, Schalk Van der Merwe, Jacques Pirenne, Frederik Nevens
Currently, nucleos(t)ide analogs (NAs) in monotherapy are favored as prophylaxis against hepatitis B recurrence after liver transplantation. However, in patients at risk of renal failure, renal safety of NAs is of concern. We investigated the safety and efficacy of subcutaneous (SC) hepatitis B immunoglobulins (HBIG) in monotherapy. This is a single-arm prospective trial in patients transplanted >1 year. We included 43 Caucasian patients. The majority was treated with calcineurin inhibitors, and several patients had other risk factors for renal impairment as well: diabetes mellitus (n = 10/43), arterial hypertension (n = 11/43), and hyperlipidemia (=10/43)...
May 2018: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/29232664/vaccination-practices-in-pediatric-dialysis-patients-across-europe-a-european-pediatric-dialysis-working-group-and-european-society-for-pediatric-nephrology-dialysis-working-group-study
#8
Sevcan A Bakkaloğlu, Yesim Özdemir Atikel, Fabio Paglialonga, Constantinos J Stefanidis, Varvara Askiti, Enrico Vidal, Gema Ariceta, Engin Melek, Enrico Verrina, Nikoleta Printza, Karel Vondrak, Aleksandra Zurowska, Ilona Zagozdzon, Mesiha Ekim, Elif Nursel Özmert, Stephanie Dufek, Augustina Jankauskiene, Claus Peter Schmitt, Eszter Lévai, Johan Vande Walle, Nur Canpolat, Tuula Holtta, Michel Fischbach, Guenter Klaus, Christoph Aufricht, Rukshana Shroff, Alberto Edefonti
BACKGROUND: Data on the immunization practices in pediatric chronic kidney disease (CKD) patients are scarce. The purpose of this study was to evaluate current vaccination practices for children on dialysis across European pediatric nephrology centers. METHODS: A total of 18 tertiary pediatric nephrology centers from 12 European countries were included in the study. The data on universal national immunization programs and immunization practices for children with chronic disease or risk were recorded from European Center for Disease Prevention and Control and the World Health Organization...
2018: Nephron
https://www.readbyqxmd.com/read/28951777/hepatitis-b-in-renal-transplant-patients
#9
REVIEW
Smaragdi Marinaki, Kyriaki Kolovou, Stratigoula Sakellariou, John N Boletis, Ioanna K Delladetsima
Hepatitis B virus (HBV) poses a significant challenge for both dialysis patients and kidney transplant recipients despite its decreasing rates, especially in developed countries. The best preventive method is vaccination. Patients with chronic renal disease should ideally be vaccinated prior to dialysis, otherwise, reinforced vaccination practices and close antibody titer monitoring should be applied while on dialysis. HBV infected dialysis patients who are renal transplant candidates must be thoroughly examined by HBV-DNA, and liver enzyme testing and by liver biopsy...
September 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28884132/renal-function-improvement-by-telbivudine-in-liver-transplant-recipients-with-chronic-kidney-disease
#10
RANDOMIZED CONTROLLED TRIAL
Wei-Chen Lee, Tsung-Han Wu, Yu-Chao Wang, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Ching-Song Lee
Chronic renal failure is a frequent complication in liver transplantation. Telbivudine, anti-hepatitis B virus (HBV) nucleoside, can improve renal function. It is interesting if using telbivudine for prophylaxis of HBV recurrence has additional value on renal function improvement. 120 liver transplant recipients with lamivudine prophylaxis for HBV recurrence were 1 : 1 randomized into lamivudine-continuous ( n = 60) and telbivudine-replacement ( n = 60) groups. Fifty-eight patients in lamivudine-continuous group and 54 in telbivudine-replacement group completed the study...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28828170/hcv-infected-renal-transplant-recipients-our-experience-before-the-availability-of-new-antiviral-drugs
#11
A R Fernandes, I J Laranjinha, R Birne, P Matias, C Jorge, T Adragão, M Bruges, A Weigert, D Machado
BACKGROUND: Natural history of HCV-infected renal transplant recipients is about to change with the invention of new drugs available for the treatment of HCV. OBJECTIVE: To analyze the evolution of renal transplant recipients infected with HCV in 30 years of activity of a Renal Transplantation Unit. METHODS: We studied 1334 patients who underwent renal transplantation between 1985 and 2015. RESULTS: 189 (14.2%) of these 1334 were found HCV seropositive...
2017: International Journal of Organ Transplantation Medicine
https://www.readbyqxmd.com/read/28774413/management-of-hepatitis-b-in-special-populations
#12
REVIEW
Kali Zhou, Norah Terrault
Special populations infected with chronic HBV include those with decompensated cirrhosis, coinfections (HIV, HCV, HDV), hemodialysis and renal failure, immunosuppressed including transplant patients, children and women in pregnancy. These populations differ in their natural history and risk for liver-related complications, the indications for anti-HBV therapy as well as the recommendations regarding the HBV drugs used, duration of therapy and anticipated endpoints. Reflecting the special populations with substantive changes in management in recent years, this review focuses on HBV-HIV coinfected patients, immunosuppressed patients at risk for reactivation, liver transplant recipients and pregnant women...
June 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28748878/assessment-of-hepatic-fibrosis-by-fibroscan-in-egyptian-chronic-hemodialysis-patients-with-chronic-hepatitis-c-genotype-4-a-single-center-study
#13
Bahaa El-Din Moustafa Zayed, Aisha Elsharkawy, Mahmoud Abdou, Dina Sabry Abd Al Fatah, Tarek Hussein El-Shabony
Assessing hepatic fibrosis in hemodialysis patients with chronic hepatitis C (CHC) can help to evaluate the long-term prognosis, complications of hepatitis C virus (HCV) as well as eligibility for renal transplantation,. Our aim was to assess liver fibrosis in Egyptian hemodialysis (HD) patients infected with CHC genotype 4 using a fibroscan. This cross-sectional observational study was conducted over two years on a cohort of 134 Egyptian patients on prevalent HD at Kasr Al Ainy Hospital. All patients were subjected to routine laboratory evaluation including, hepatitis B surface antigen, hepatitis B core antibody, hepatitis Be antigen, hepatitis C antibody (HCVAb) and human immunodeficiency virus antibody, quantitative polymerase chain reaction (PCR) for both HCV and hepatitis B virus (HBV), serum hyaluronic acid level, and alpha-fetoprotein (AFP)...
July 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28457920/antibody-response-to-hbv-vaccination-on-dialysis-does-not-correlate-with-the-development-of-denovo-anti-hla-antibodies-after-renal-transplantation
#14
Teresa Kauke, Maximilian Link, Markus Rentsch, Manfred Stangl, Markus Guba, Joachim Andrassy, Jens Werner, Bruno Meiser, Michael Fischereder, Antje Habicht
BACKGROUND: Response to Hepatitis B virus (HBV) vaccination can be diminished in some (50-80%) but not all dialysis patients. We hypothesized, that the response to vaccination on dialysis may correlate with the development of anti-HLA antibodies after renal transplantation and might therefore be a valuable parameter to predict alloresponses. METHODS: The response to HBV vaccination on dialysis and the development of deNovo anti-HLA antibodies post-transplant was analyzed in 188 non-immunized renal transplant recipients...
June 2017: Transplant Immunology
https://www.readbyqxmd.com/read/28107607/epidemiology-update-for-hepatitis-c-virus-and-hepatitis-b-virus-in-end-stage-renal-disease-in-france
#15
Corinne Isnard Bagnis, Cécile Couchoud, Marc Bowens, Ayman Sarraj, Gilbert Deray, Jérôme Tourret, Patrice Cacoub, Sophie Tezenas du Montcel
BACKGROUND & AIMS: Risk for HCV/HBV infection is increased in end-stage renal disease patients. We generate updated epidemiological data. METHODS: Based on the National French registry for end-stage renal disease patients, we extracted data for patients who started dialysis or pre-emptive transplantation between January 2005 and December 2013. A positive serum HBs Ag and/or a positive HCV RNA defined HBV and HCV infections, respectively. RESULTS: In all, 72 948 patients were included among which 62...
June 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27917563/outcome-of-hepatitis-b-and-c-virus-associated-hepatocellular-carcinoma-occurring-after-renal-transplantation
#16
N Kanaan, C Raggi, E Goffin, M De Meyer, M Mourad, M Jadoul, C Beguin, B Kabamba, I Borbath, Y Pirson, Z Hassoun
Kidney transplant recipients (KTR) are subjected to immunosuppressive therapy that can enhance hepatitis B and C virus replication, leading to cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to assess the prevalence and outcome of HCC in KTR. Case-control study. Patients with chronic HBV and/or HCV infection who underwent kidney transplantation between 1976 and 2011 and subsequently developed HCC were compared to a control group of patients with chronic HBV and/or HCV infection, matched for gender and age at HCC diagnosis, who did not receive kidney transplantation...
May 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27800206/immune-complex-mediated-glomerulonephritis-with-acute-thrombotic-microangiopathy-following-newly-detected-hepatitis-b-virus-infection-in-a-kidney-transplant-recipient
#17
Tracey Salter, Hannah Burton, Sam Douthwaite, William Newsholme, Catherine Horsfield, Rachel Hilton
Hepatitis B virus (HBV) presents a risk to patients and staff in renal units. To minimise viral transmission, there are international and UK guidelines recommending HBV immunisation for patients commencing renal replacement therapy (RRT) and HBV surveillance in kidney transplant recipients. We report the case of a 56-year-old male who was immunised against HBV before starting haemodialysis. He received a deceased donor kidney transplant three years later, at which time there was no evidence of HBV infection...
2016: Case Reports in Transplantation
https://www.readbyqxmd.com/read/27763680/humoral-and-cellular-responses-to-a-single-dose-of-fendrix-in-renal-transplant-recipients-with-non-response-to-previous-hepatitis-b-vaccination
#18
M Lindemann, M Zaslavskaya, M Fiedler, B Wilde, F M Heinemann, A Heinold, P A Horn, O Witzke
Approximately 70% of kidney transplant recipients are non-responders to conventional hepatitis B virus (HBV) vaccines. We examined whether Fendrix™, an HBV vaccine containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL) as adjuvant, could induce HBV immunity in these patients and compared their vaccination efficacy with healthy controls tested previously by the same assays. We selected 35 kidney transplant recipients who had been vaccinated at least thrice against HBV but had never displayed anti-HBs antibodies...
January 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/27499773/immunogenicity-of-four-doses-of-double-strength-intramuscular-hepatitis-b
#19
Seyed Ali Asghar Fakhrmousavi, Azar Hadadi, Seyed Hamed Hosseini, Maryam Rahbar, Reza Hamidian, Amitis Ramezani, Gholamreza Pourmand, Effat Razeghi
BACKGROUND: Hepatitis B virus potentially accelerates graft rejection and mortality in renal transplantation population. Vaccination of graft candidates without prior immunization against HBV seems essential before transplantation but some candidates of transplantation have not received HBV vaccine at the time of receiving graft. We aimed to evaluate immunogenicity of an enhanced regimen (4 doses of double-strength intramuscular shots) after kidney transplantation in candidates without history of prior HBV vaccination...
2016: Iranian Journal of Pathology
https://www.readbyqxmd.com/read/27311622/hbv-associated-acute-liver-failure-after-immunosuppression-and-risk-of-death
#20
MULTICENTER STUDY
Constantine J Karvellas, Filipe S Cardoso, Michelle Gottfried, K Rajender Reddy, A James Hanje, Daniel Ganger, William M Lee
BACKGROUND & AIMS: Acute liver failure (ALF) caused by hepatitis B virus (HBV) infection can occur after immunosuppressive treatment and be fatal, although it might be preventable. We aimed to characterize the causes, clinical course, and short-term outcomes of HBV-associated ALF after immune-suppressive therapy, compared with patients with HBV-associated ALF without immunosuppression (control subjects). METHODS: We performed a retrospective multicenter study of 156 consecutive patients diagnosed with HBV-associated ALF (22 with a solid or blood malignancy) enrolled in the Acute Liver Failure Study Group registry from January 1998 through April 2015...
January 2017: Clinical Gastroenterology and Hepatology
keyword
keyword
161935
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"